ATE207356T1 - Verwendung von tiagabin zur behandlung von schlafstörungen - Google Patents

Verwendung von tiagabin zur behandlung von schlafstörungen

Info

Publication number
ATE207356T1
ATE207356T1 AT98102356T AT98102356T ATE207356T1 AT E207356 T1 ATE207356 T1 AT E207356T1 AT 98102356 T AT98102356 T AT 98102356T AT 98102356 T AT98102356 T AT 98102356T AT E207356 T1 ATE207356 T1 AT E207356T1
Authority
AT
Austria
Prior art keywords
sleep disorders
tiagabine
treat sleep
sub
treat
Prior art date
Application number
AT98102356T
Other languages
English (en)
Inventor
Marike Lancel
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7766768&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE207356(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE207356T1 publication Critical patent/ATE207356T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AT98102356T 1995-07-13 1996-07-10 Verwendung von tiagabin zur behandlung von schlafstörungen ATE207356T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19525598A DE19525598C2 (de) 1995-07-13 1995-07-13 Schlafmittel

Publications (1)

Publication Number Publication Date
ATE207356T1 true ATE207356T1 (de) 2001-11-15

Family

ID=7766768

Family Applications (3)

Application Number Title Priority Date Filing Date
AT98102356T ATE207356T1 (de) 1995-07-13 1996-07-10 Verwendung von tiagabin zur behandlung von schlafstörungen
AT98102355T ATE207352T1 (de) 1995-07-13 1996-07-10 Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
AT96925704T ATE207349T1 (de) 1995-07-13 1996-07-10 Thip zur behandlung von schlafstörungen

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT98102355T ATE207352T1 (de) 1995-07-13 1996-07-10 Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
AT96925704T ATE207349T1 (de) 1995-07-13 1996-07-10 Thip zur behandlung von schlafstörungen

Country Status (12)

Country Link
US (1) US5929065A (de)
EP (3) EP0840601B1 (de)
JP (3) JP3754705B2 (de)
AT (3) ATE207356T1 (de)
AU (1) AU723954B2 (de)
CA (1) CA2226582C (de)
CL (1) CL2003002785A1 (de)
DE (4) DE19525598C2 (de)
DK (3) DK0840601T3 (de)
ES (3) ES2166110T3 (de)
PT (3) PT840601E (de)
WO (1) WO1997002813A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
JP2001511450A (ja) * 1997-08-01 2001-08-14 エラン コーポレーシヨン ピーエルシー チアガビンを含有する制御放出性の医薬組成物
EP1220658A1 (de) * 1999-09-28 2002-07-10 H. Lundbeck A/S Schmelzgranulierte zusammensetzung und aus dieser hergestellte darreichungsform mit modifizierter freisetzung
PL359872A1 (en) * 2000-06-26 2004-09-06 Warner-Lambert Company Gabapentin analogues for sleep disorders
AU2002338855B2 (en) * 2001-05-21 2007-08-16 H. Lundbeck A/S Granular preparations of gaboxadol
BRPI0410857A (pt) 2003-06-25 2006-07-04 Lundbeck & Co As H método para o tratamento de depressão, uso de gaboxadol, e, composição farmacêutica
AR045540A1 (es) 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
US20070032553A1 (en) * 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
TW200528098A (en) * 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
EP1696959A2 (de) * 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin-kombinationstherapie zur verbesserung der schlafqualität
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
DK1742624T3 (da) * 2004-02-18 2010-03-08 Sepracor Inc Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet
JP2007530604A (ja) * 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (de) 2005-01-28 2008-01-23 Merck & Co Inc Polymorphe formen eines gabaa-agonisten
JP5380930B2 (ja) * 2007-07-24 2014-01-08 大正製薬株式会社 睡眠改善剤
RS62007B1 (sr) 2014-06-06 2021-07-30 Ovid Therapeutics Inc Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma
LT3274331T (lt) 2015-03-24 2020-04-10 H. Lundbeck A/S 4,5,6,7-tetrahidroizozaksolo[5,4-c]piridin-3-olio gamybos būdas
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
EP4541420A3 (de) 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Verfahren zur behandlung von entwicklungsstörungen mit gaboxadol
EP3481387A4 (de) 2016-08-11 2020-04-08 Ovid Therapeutics Inc Verfahren und zusammensetzungen zur behandlung von epileptischen erkrankungen
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
JP2022514194A (ja) 2018-11-21 2022-02-10 セルテゴ セラピューティクス インコーポレイテッド 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
US11986714B2 (en) 2018-12-14 2024-05-21 Raimondo Fazio Martial arts training device
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
US11364228B2 (en) 2019-12-18 2022-06-21 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
KR102773472B1 (ko) * 2021-05-21 2025-02-27 한국식품연구원 구릿대 추출물을 유효성분으로 포함하는 수면장애 또는 불면증의 예방, 개선 또는 치료용 조성물
WO2023015395A1 (en) * 2021-08-11 2023-02-16 Psyched Wellness Ltd. Amanita muscaria extracts and compounds and their beneficial and therapeutic use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4786647A (en) * 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
US5167228A (en) * 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5185446A (en) * 1990-09-04 1993-02-09 Neurogen Corporation Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands
DK58291D0 (da) * 1991-04-02 1991-04-02 Novo Nordisk As Krystalinsk stof og dets fremstilling
US6077839A (en) * 1992-03-19 2000-06-20 Allergan Sales, Inc. Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists

Also Published As

Publication number Publication date
CA2226582A1 (en) 1997-01-30
AU6613796A (en) 1997-02-10
DE19525598A1 (de) 1997-01-16
JP2009057382A (ja) 2009-03-19
DE19525598C2 (de) 1997-09-25
JPH11509194A (ja) 1999-08-17
EP0867184B1 (de) 2001-10-24
PT840601E (pt) 2002-04-29
EP0867184A1 (de) 1998-09-30
JP3754705B2 (ja) 2006-03-15
ES2165990T3 (es) 2002-04-01
EP0867178A1 (de) 1998-09-30
CL2003002785A1 (es) 2005-04-08
ES2166111T3 (es) 2002-04-01
EP0867178B1 (de) 2001-10-24
DK0840601T3 (da) 2002-02-18
DE69616333D1 (de) 2001-11-29
EP0840601A1 (de) 1998-05-13
DK0867178T3 (da) 2002-02-18
DE69616333T2 (de) 2002-07-04
EP0840601B1 (de) 2001-10-24
PT867178E (pt) 2002-04-29
ATE207349T1 (de) 2001-11-15
JP2005047925A (ja) 2005-02-24
DK0867184T3 (da) 2002-02-18
PT867184E (pt) 2002-04-29
DE69616375T2 (de) 2002-07-11
ATE207352T1 (de) 2001-11-15
DE69616376D1 (de) 2001-11-29
ES2166110T3 (es) 2002-04-01
DE69616376T2 (de) 2002-06-27
AU723954B2 (en) 2000-09-07
US5929065A (en) 1999-07-27
CA2226582C (en) 2008-02-19
WO1997002813A1 (en) 1997-01-30
DE69616375D1 (de) 2001-11-29

Similar Documents

Publication Publication Date Title
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE69631134D1 (de) Verfahren zur bekämpfung infektiöser krankheiten unter verwendung dikationischer bis-benzimidazole
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE315390T1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
EP1056458A4 (de) Methoden zur behandlung von schmerzen, einscliesslich chronischen und frauenspezifischen schmerzen
DE69623767D1 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
DE60024408D1 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
DE69807586D1 (de) Verwendung eines Alkylendioxybenzolderivats zur Behandlung von zirkadianen Schlafstörungen
DE69941134D1 (de) Verwendung von R (+)- g(a)-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol zur Behandlung von Schlafstörungen
ATE150645T1 (de) Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee